Stock Ideas
New
Stocks
Funds
Screener
Sectors
Watchlists
MLAB

MLAB - Mesa Laboratories Inc Stock Price, Fair Value and News

92.72USD-2.70 (-2.83%)Market Closed

Market Summary

MLAB
USD92.72-2.70
Market Closed
-2.83%

MLAB Stock Price

View Fullscreen

MLAB RSI Chart

MLAB Valuation

Market Cap

500.1M

Price/Earnings (Trailing)

527.57

Price/Sales (Trailing)

2.35

EV/EBITDA

16.86

Price/Free Cashflow

12.29

MLAB Price/Sales (Trailing)

MLAB Profitability

Operating Margin

61.02%

EBT Margin

-0.28%

Return on Equity

0.24%

Return on Assets

0.13%

Free Cashflow Yield

8.14%

MLAB Fundamentals

MLAB Revenue

Revenue (TTM)

212.9M

Rev. Growth (Yr)

-1.5%

Rev. Growth (Qtr)

0.58%

MLAB Earnings

Earnings (TTM)

948.0K

Earnings Growth (Yr)

369.18%

Earnings Growth (Qtr)

272.03%

Breaking Down MLAB Revenue

Last 7 days

-13.6%

Last 30 days

-21.5%

Last 90 days

-8.3%

Trailing 12 Months

-31.7%

How does MLAB drawdown profile look like?

MLAB Financial Health

Current Ratio

2.68

Debt/Equity

0.42

Debt/Cashflow

0.26

MLAB Investor Care

Dividend Yield

0.69%

Dividend/Share (TTM)

0.64

Shares Dilution (1Y)

0.90%

Diluted EPS (TTM)

0.18

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
2023219.1M219.3M213.7M212.9M
2022184.3M199.9M222.8M222.4M
2021133.9M138.9M142.9M163.4M
2020117.7M121.3M127.7M130.2M
2019103.1M104.3M105.0M109.9M
201896.2M98.6M100.6M103.6M
201793.7M95.2M93.8M93.6M
201684.7M87.6M90.2M94.2M
201571.3M73.1M76.3M78.4M
201452.7M57.9M63.8M68.5M
201346.4M47.1M48.1M49.8M
201239.6M40.9M42.9M44.6M
201134.2M35.7M37.4M39.0M
20100000
GRUFITY'S FAIR VALUE MODEL

Stocks Marked 'Very Cheap' by Grufity's Fair Value Model Have Outperformed Russell 2000 Index

Small Caps and Mid Caps are mostly overlooked by investors as all the focus goes to Magnificent 7. These stocks that are not part of the beauty contest require a deeper look. However, all large cap stocks were once small caps. Grufity's Fair Value model opens up this unverse as it separates high-performing, rewarding stocks from low-performing risky stocks. <b>Russell 2000 stocks that were marked 'Very Cheap' by the model doubled in three years while the index was flat.</b>

PurpleZone


Returns of $10,000 invested in:

Very Cheap Stocks: $21,859
Russell 2000 Index: $10,334
Very Expensive Stocks: $8,224


Russell 2000 stocks considered 'Very Cheap' by the model greatly outperformed Russell 2000 index and the 'Very Expensive' bucket over past three years.

Russell 2000 Index
Very Expensive Stocks
Very Cheap Stocks
Try For Just $1.99

Tracking the Latest Insider Buys and Sells of Mesa Laboratories Inc

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
Dec 15, 2023
archbold brian david
sold
-168,540
112
-1,500
svp operations
Nov 09, 2023
sullivan john james
gifted
-
-
200
-
Nov 09, 2023
sullivan john james
gifted
-
-
-2,200
-
Sep 15, 2023
schmieder john bradley
sold
-123,740
123
-1,000
-
Sep 14, 2023
schmieder john bradley
sold
-369,150
123
-3,000
-
Sep 13, 2023
schmieder john bradley
sold
-369,965
123
-3,000
-
Sep 01, 2023
owens gary m
sold
-285,640
142
-2,000
president and ceo
Sep 01, 2023
owens gary m
acquired
272,840
136
2,000
president and ceo
Aug 15, 2023
hall shannon
acquired
-
-
754
-
Aug 15, 2023
ladiwala shiraz shabanali
acquired
-
-
40.00
-

1–10 of 50

Which funds bought or sold MLAB recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
Jun 11, 2024
EverSource Wealth Advisors, LLC
reduced
-76.6
-3,757
1,167
-%
May 28, 2024
TEACHERS RETIREMENT SYSTEM OF THE STATE OF KENTUCKY
unchanged
-
8,000
177,000
-%
May 16, 2024
Pineridge Advisors LLC
sold off
-100
-1,467
-
-%
May 16, 2024
COMERICA BANK
reduced
-5.95
-71,319
4,696,680
0.02%
May 16, 2024
Motley Fool Asset Management LLC
added
89.32
896,786
1,809,230
0.12%
May 16, 2024
CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM
reduced
-4.96
-2,715
588,921
-%
May 16, 2024
Beacon Capital Management, LLC
new
-
658
658
-%
May 15, 2024
GOLDMAN SACHS GROUP INC
reduced
-87.94
-6,052,080
875,208
-%
May 15, 2024
AMERIPRISE FINANCIAL INC
reduced
-1.3
193,180
5,913,570
-%
May 15, 2024
KENNEDY CAPITAL MANAGEMENT LLC
reduced
-44.24
-4,666,090
6,551,320
0.14%

1–10 of 46

Are Funds Buying or Selling MLAB?

Are funds buying MLAB calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own MLAB
No. of Funds

Unveiling Mesa Laboratories Inc's Major ShareHolders

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Feb 13, 2024
vanguard group inc
6.87%
370,278
SC 13G/A
Jan 23, 2024
royce & associates lp
5.%
269,645
SC 13G/A
Jan 22, 2024
blackrock inc.
15.7%
845,773
SC 13G/A
Jan 05, 2024
conestoga capital advisors, llc
11.45%
617,612
SC 13G/A
Feb 09, 2023
vanguard group inc
6.73%
359,293
SC 13G/A
Feb 02, 2023
invesco ltd.
4.4%
232,427
SC 13G/A
Jan 27, 2023
royce & associates lp
3.01%
160,577
SC 13G/A
Jan 26, 2023
blackrock inc.
16.4%
874,324
SC 13G/A
Jan 20, 2023
blackrock inc.
16.4%
874,324
SC 13G/A
Jan 18, 2023
conestoga capital advisors, llc
11.34%
605,117
SC 13G/A

Recent SEC filings of Mesa Laboratories Inc

View All Filings
Date Filed Form Type Document
Jun 05, 2024
8-K
Current Report
Apr 08, 2024
8-K
Current Report
Apr 03, 2024
4
Insider Trading
Apr 03, 2024
4
Insider Trading
Apr 03, 2024
4
Insider Trading
Apr 03, 2024
4
Insider Trading
Apr 02, 2024
8-K
Current Report
Apr 02, 2024
UPLOAD
UPLOAD
Mar 26, 2024
4
Insider Trading
Mar 25, 2024
CORRESP
CORRESP

Peers (Alternatives to Mesa Laboratories Inc)

NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
3.3T
381.6B
14.25% 16.41%
32.71
8.6
-0.90% 6.43%
41.4B
12.8B
-46.34% -14.36%
20.34
3.23
1.52% 6.35%
32.6B
12.4B
8.93% 14.53%
52.18
2.63
-9.51% -31.36%
25.7B
6.1B
-5.81% 4.99%
28.55
4.19
3.71% 17.79%
12.9B
26.4B
10.49% 20.23%
12.79
0.49
-7.32% 26.86%
MID-CAP
7.9B
847.2M
-1.74% -17.23%
79.71
9.38
-8.39% -42.67%
7.0B
31.3B
2.50% -4.13%
9.86
0.22
-14.93% -46.55%
5.5B
740.8M
-2.97% 25.43%
54
7.46
25.07% 42.99%
4.8B
24.7B
0.30% 10.21%
8.46
0.2
-6.09% -33.76%
2.8B
988.8M
2.55% 9.32%
28.2
2.8
8.64% 13.26%
SMALL-CAP
1.7B
2.8B
-4.68% 38.90%
20.44
0.61
-10.09% 0.74%
1.5B
2.8B
0.05% 64.77%
22.47
0.53
-4.25% -5.27%
223.6M
986.2M
-16.38% -64.34%
-0.62
0.23
-6.21% -5303.34%
25.4M
26.4M
1.16% -40.07%
33.09
0.96
-2.48% -64.63%
22.4M
56.7M
21.66% 48.06%
-3.8
0.59
-41.04% -726.48%

Mesa Laboratories Inc News

Latest updates
MarketBeat5 hours ago
MarketBeat10 Jun 202409:11 pm
Yahoo New Zealand News09 Jun 202401:16 am
MarketBeat04 Jun 202407:07 pm
MarketBeat30 May 202407:00 am

Mesa Laboratories Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)
(In Thousands)
Income Statement (Quarterly)
(In Thousands)
(*) denotes actual numbers (not divided by Thousands)
Description(%) Q/Q2023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q4
Revenue0.6%53.0053.0051.0056.0054.0059.0050.0059.0055.0036.0035.0038.0034.0032.0030.0034.0032.0026.0026.0026.0027.00
Cost Of Revenue-4.7%20.0021.0019.0022.0022.0022.0019.0024.0026.0013.0013.0013.0014.0011.0010.0015.0017.0010.0010.0011.0011.00
Gross Profit4.0%33.0032.0031.0033.0033.0036.0031.0035.0029.0023.0022.0025.0021.0021.0020.0019.0015.0016.0016.0016.0016.00
Operating Expenses4.0%33.0032.0032.0033.0029.0032.0036.0035.0031.0019.0019.0020.0021.0017.0017.0018.0018.0011.0011.0013.0014.00
  S&GA Expenses0.9%10.0010.009.0010.008.009.0010.0010.009.005.005.006.005.004.004.004.004.002.002.003.002.00
  R&D Expenses-14.0%4.005.005.005.005.005.006.005.005.003.003.003.003.002.003.002.002.001.001.001.001.00
EBITDA Margin1.4%0.18*0.18*0.19*0.17*0.24*0.21*0.22*0.26*0.25*0.25*0.25*0.26*---------
Interest Expenses105.1%2.001.001.001.001.001.001.001.001.001.001.002.002.002.002.002.002.001.000.000.000.00
Income Taxes-78.9%-0.17-0.09-0.39-0.891.002.00-3.972.00-0.281.00-0.581.00-1.18-0.29-0.461.00-0.571.001.001.000.00
Earnings Before Taxes246.9%2.00-1.32-0.94-0.282.003.00-5.41-0.05-2.345.001.005.00-5.732.001.00-0.23-5.084.005.002.001.00
EBT Margin4.4%0.00*0.00*0.02*0.00*0.00*-0.02*-0.02*0.02*0.05*0.04*0.02*0.02*---------
Net Income272.0%2.00-1.23-0.551.000.001.00-1.44-1.78-2.064.002.004.00-4.543.001.00-1.55-4.503.005.001.001.00
Net Income Margin232.7%0.00*0.00*0.01*0.00*-0.01*-0.02*-0.01*0.01*0.05*0.04*0.03*0.02*---------
Free Cashflow13.8%10.009.0010.0011.006.009.00-3.049.0014.003.009.0012.00---------
Balance Sheet
(In Millions)
Balance Sheet
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q4
Assets16.4%742637643662663656686707722609612601622589577409423392160157158
  Current Assets0.6%11811811511911411612812412131931530429528027012312127134.0034.0033.00
    Cash Equivalents-20.8%28.0036.0032.0033.0026.0032.0044.0049.0052.0027827626425424223181.0074.002457.0010.006.00
  Inventory9.4%36.0033.0036.0035.0034.0028.0027.0025.0024.0012.0025.0011.0012.0012.0013.0011.0019.007.007.007.008.00
  Net PPE11.2%32.0029.0028.0028.0028.0028.0028.0029.0030.0022.0022.0022.0022.0022.0022.0022.0022.0022.0022.0022.0023.00
  Goodwill22.2%34628328428628627828429129416016316116615615414219067.0067.0066.00-
Liabilities35.8%33924925526827628230531432521021319520919719418918916341.0045.0051.00
  Current Liabilities11.0%44.0040.0039.0043.0042.0042.0044.0048.0047.0029.0033.0033.0028.0020.0020.0026.0025.0017.0021.0024.0021.00
  Long Term Debt0.1%17117117117017017017016916916916914614414314214013913818.0021.0027.00
    LT Debt, Current-------------------2.002.002.00
    LT Debt, Non Current0.1%17117117117017017017016916916916914614414314214013913818.0021.0027.00
Shareholder's Equity3.9%403388388393387374380394396399399406413392382220235230119111108
  Retained Earnings1.8%72.0071.0073.0074.0074.0075.0074.0077.0079.0082.0079.0072.0069.0075.0072.0072.0074.0080.0077.0073.0073.00
Accumulated Depreciation5.9%23.0021.0020.0020.0020.0019.0018.0018.0018.00--16.0015.0014.0013.0013.0015.00--11.00-
Shares Outstanding0.0%5.005.005.005.005.005.005.005.005.005.005.005.00---------
Float------713---1,454---1,221---973---
Cashflow (Last 12 Months)
(In Thousands)
Cashflow (Quarterly)
(In Thousands)
Description(%) Q/Q2023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q4
Cashflow From Operations18.0%11,5359,7769,93912,5197,71810,557-2,8119,30215,8984,4349,58913,52010,94310,3502,2608,83211,0076,42572410,26210,092
  Share Based Compensation-6.0%2,9933,1832,9682,6792,0564,3713,4323,4523,7032,0392,1972,3813,6112,0081,2682153,2601,1828681,788695
Cashflow From Investing-12648.9%-80,828-634-270-1,026-6,604-1,639-225-782-302,852-938-653-1,038-247-491-216-548-181,939-317-2,781-55.00-5,198
Cashflow From Financing1194.4%60,848-5,560-9,519-4,392-8,883-18,646-1,407-10,04761,2001,158265-1,047171219146,885394-357232,155-915-5,615-4,757
  Dividend Payments0%862862859856855852843844837834824824819818704703698697624619617
Get Full Access to Grufity – and Unlimited Downloads
Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.
Try For Just $1.99

MLAB Income Statement

2023-12-31
Condensed Consolidated Statements of Income (Unaudited) - USD ($)
shares in Thousands, $ in Thousands
3 Months Ended9 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2023
Dec. 31, 2022
Revenues$ 53,473$ 54,287$ 157,283$ 163,489
Cost of revenues20,07121,52260,58962,997
Gross profit33,40232,76596,694100,492
Operating expense:    
Selling9,7378,43728,36327,660
General and administrative19,43816,12955,02454,543
Research and development4,2944,79714,09815,486
Total operating expense33,46929,36397,48597,689
Operating (loss) income(67)3,402(791)2,803
Nonoperating expense:    
Interest expense and amortization of debt issuance costs1,8561,1623,8093,390
Other (income) expense, net(3,869)324(4,284)(475)
Total nonoperating (income) expense, net(2,013)1,486(475)2,915
Earnings (loss) before income taxes1,9461,916(316)(112)
Income tax (benefit) expense(170)1,465(653)(431)
Net (loss) income$ 2,116$ 451$ 337$ 319
Earnings per share:    
Basic earnings per share (in dollars per share)$ 0.39$ 0.08$ 0.06$ 0.06
Diluted earnings per share (in dollars per share)$ 0.39$ 0.08$ 0.06$ 0.06
Weighted-average common shares outstanding:    
Basic (in shares)5,3935,3395,3845,312
Fully diluted shares (in shares)5,3965,3605,3945,354

MLAB Balance Sheet

2023-12-31
Condensed Consolidated Balance Sheets (Current Period Unaudited) - USD ($)
$ in Thousands
Dec. 31, 2023
Mar. 31, 2023
Cash and cash equivalents$ 28,224$ 32,910
Accounts receivable, less allowance for doubtful accounts of $1,363 and $849, respectively36,02342,551
Inventories35,97334,642
Prepaid expenses and other18,1358,872
Total current assets118,355118,975
Noncurrent assets:  
Property, plant and equipment, net of accumulated depreciation of $22,574 and $19,768 respectively31,77528,149
Deferred tax asset1,0921,076
Other assets11,59010,373
Intangible assets232,774216,815
Goodwill346,183286,444
Total assets741,769661,832
LIABILITIES AND STOCKHOLDERS’ EQUITY  
Accounts payable4,5546,134
Accrued payroll and benefits9,3809,433
Unearned revenues14,35715,694
Other accrued expenses15,89212,098
Total current liabilities44,18343,359
Noncurrent liabilities:  
Deferred tax liability44,34034,028
Other long-term liabilities17,3207,693
Credit facility62,00013,000
Convertible senior notes, net of debt issuance costs170,965170,272
Total liabilities338,808268,352
Stockholders’ equity:  
Common stock, no par value; authorized 25,000,000 shares; issued and outstanding, 5,394,043 and 5,369,466 shares, respectively340,852332,076
Retained earnings71,95374,199
Accumulated other comprehensive (loss)(9,844)(12,795)
Total stockholders’ equity402,961393,480
Total liabilities and stockholders’ equity741,769661,832
Customer Relationships [Member]  
Noncurrent assets:  
Intangible assets162,890152,189
Intellectual Property [Member]  
Noncurrent assets:  
Intangible assets45,75346,400
Other Intangible Assets [Member]  
Noncurrent assets:  
Intangible assets$ 24,131$ 18,226
MLAB
Mesa Laboratories, Inc. develops, manufactures, and sells life sciences tools and quality control products and services in North America, Europe, the Asia Pacific, and internationally. It operates in four segments: Clinical Genomics, Sterilization and Disinfection Control, Biopharmaceutical Development, and Calibration Solutions. The Clinical Genomics segment develops, manufactures, and sells genetic analysis tools that include MassARRAY system and consumables, including chips, panels, and chemical reagent solutions used by clinical labs to perform genomic clinical testing in various therapeutic areas, such as screenings for hereditary diseases, pharmacogenetics, and oncology related applications. The Sterilization and Disinfection Control segment manufactures and sells biological, cleaning, and chemical indicators that are used to assess the effectiveness of sterilization and disinfection processes in the hospital, dental, medical device, and pharmaceutical industries. This segment also provides testing and laboratory services primarily to the dental industry. The Biopharmaceutical Development segment develops, manufactures, and sells automated systems for protein analysis and peptide synthesis solutions. This segment's solutions include protein analysis comprising analysis equipment, CDs, kits, and buffers; and peptide synthesizers that enable customers to automate chemical synthesis of peptides that are used in the creation of peptide therapies, biomaterials, cosmetics, and general research. The Calibration Solutions segment designs, manufactures, and markets quality control products to measure or calibrate temperature, pressure, pH, and humidity for health and safety purposes in the hospital, medical device manufacturing, pharmaceutical manufacturing, and various laboratory environments. This segment's products include continuous monitoring systems, dialysate meters and consumables, data loggers, gas flow calibration and air sampling equipment, and torque testing systems. The company was incorporated in 1982 and is headquartered in Lakewood, Colorado.
 CEO
 WEBSITEmesalabs.com
 INDUSTRYConsumer Electronics
 EMPLOYEES698

Mesa Laboratories Inc Frequently Asked Questions


What is the ticker symbol for Mesa Laboratories Inc? What does MLAB stand for in stocks?

MLAB is the stock ticker symbol of Mesa Laboratories Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Mesa Laboratories Inc (MLAB)?

As of Thu Jun 13 2024, market cap of Mesa Laboratories Inc is 500.14 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of MLAB stock?

You can check MLAB's fair value in chart for subscribers.

What is the fair value of MLAB stock?

You can check MLAB's fair value in chart for subscribers. The fair value of Mesa Laboratories Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Mesa Laboratories Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for MLAB so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Mesa Laboratories Inc a good stock to buy?

The fair value guage provides a quick view whether MLAB is over valued or under valued. Whether Mesa Laboratories Inc is cheap or expensive depends on the assumptions which impact Mesa Laboratories Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for MLAB.

What is Mesa Laboratories Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Thu Jun 13 2024, MLAB's PE ratio (Price to Earnings) is 527.57 and Price to Sales (PS) ratio is 2.35. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. MLAB PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Mesa Laboratories Inc's stock?

In the past 10 years, Mesa Laboratories Inc has provided 0.018 (multiply by 100 for percentage) rate of return.